The next step to approaching central nervous system metastasis in HER-2-positive metastatic breast cancer patients

Asia-Pacific Journal of Clinical Oncology

Volumn 2, Issue 1, 2006, Pages 6-8

  Matsumoto, Koji ^a   Shimizu, Chikako ^a   Fujiwara, Yasuhiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TEMOZOLOMIDE; TRASTUZUMAB;

BLOOD BRAIN BARRIER; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG PENETRATION; DRUG TARGETING; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GLIOBLASTOMA; GROWTH INHIBITION; HUMAN; IMMUNOHISTOCHEMISTRY; METHODOLOGY; NEUROSURGERY; NOTE; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SAMPLE SIZE; STEREOTAXIC SURGERY; TREATMENT OUTCOME; TUMOR GROWTH;

EID: 33644668507     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/j.1743-7563.2006.00044.x     Document Type: Note

References (12)

1. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-92.
2. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-72.
3. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-84.
4. Tsukada Y, Fouad A, Pickren JW, Lane WW. Central nervous system metastasis from breast carcinoma. Autopsy study. Cancer 1983; 52: 2349-54.
5. Matsumoto K, Shimizu C, Andoh M et al. Retrospective analysis of breast cancer patients with brain metastasis that occurred during trastuzumab therapy. Proceedings of the 12 th Annual Meeting of the Japanese Breast Cancer Society, 2004. Abstract 0-006.
6. Bendell JC, Domchek SM, Burstein HJ et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003; 97: 2972-7.
7. Clayton AJ, Danson S, Jolly S et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 2004; 91: 639-43.
8. Lai R, Dang CT, Malkin MG, Abrey LE. The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer 2004; 101: 810-6.
9. Miller KD, Weathers T, Haney LG et al. Occult central nervous system involvement in patients with metastatic breast cancer: Prevalence, predictive factors and impact on overall survival. Ann Oncol 2003; 14: 1072-7.
10. Shmueli E, Wigler N, Inbar M. Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment. Eur J Cancer 2004; 40: 379-82.
11. Burstein HJ, Lieberman G, Slamon DJ, Winer EP, Klein P. Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Ann Oncol 2005; 16: 1772-7.
12. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-96.